CNMD Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
335.6M
-2.3%
343.5M
+8.3%
317.0M
-15.0%
373.2M
+10.4%
337.9M
Cost of Revenue
146.4M
+0.3%
146.0M
+9.3%
133.6M
-13.8%
154.9M
-9.8%
171.8M
Gross Profit
189.1M
-4.2%
197.5M
+7.6%
183.4M
-16.0%
218.3M
+31.4%
166.1M
Operating Expenses
152.0M
-5.6%
161.1M
+1.9%
158.0M
-13.0%
181.7M
+17.8%
154.2M
R&D
15.6M
+0.6%
15.5M
-5.1%
16.3M
+9.6%
14.9M
+7.2%
13.9M
SG&A
136.4M
-6.3%
145.6M
+2.7%
141.7M
-15.0%
166.8M
+18.8%
140.3M
Operating Income
37.1M
+2.0%
36.4M
+43.2%
25.4M
-30.6%
36.6M
+208.3%
11.9M
EBITDA
11.5M
-79.3%
55.5M
+25.3%
44.3M
-20.2%
55.5M
+567.4%
-11868000
Net Income
19.8M
-14.2%
23.1M
+66.8%
13.8M
-17.4%
16.7M
+485.5%
2.9M
EPS (Basic)
$0.66
-14.3%
$0.77
+71.1%
$0.45
-16.7%
$0.54
+500.0%
$0.09
EPS (Diluted)
$0.66
-14.3%
$0.77
+71.1%
$0.45
-15.1%
$0.53
+488.9%
$0.09
Shares (Diluted)
30.1M
+0.0%
30.1M
-1.6%
30.6M
-2.3%
31.3M
+0.9%
31.1M
CONMED (CNMD) — Financials